Shouti Inc. raised $100 million in a series B round led by BVF Partners LP to advance its discovery platform for designing oral medicines and to speed up the development of its candidates. The Shanghai and California-based company has secured a total of $158 million in funding so far.
Shouti Inc. raised $100 million in a series B round led by BVF Partners LP to advance its discovery platform for designing oral medicines and to speed up the development of its candidates. The Shanghai and California-based company has secured a total of $158 million in funding so far.
DUBLIN – Novadip SA raised €19 million (US$22.1 million) in a first close of a series B round to progress its autologous bone regeneration therapy, NVD-003, on either side of the Atlantic. The company is also working on an allogeneic regenerative approach, which is still preclinical.
Cedilla Therapeutics Inc., an oncology company targeting upstream aspects of native protein degradation pathways, extended its year-ago series B with a $25 million investment bringing the round's total to $82.6 million. Proceeds from the financing will support advancement of its two lead programs, an inhibitor of the transcriptional enhanced associate domain (TEAD) transcription factor in the Hippo signaling pathway for the treatment of solid tumors and a selective inhibitor of CDK2/cyclin E for the treatment of multiple tumor types.
Prospects for Zerigo Health Inc. brightened with a series B fundraising round that brought in $43 million to support expansion of the company’s at-home ultraviolet B phototherapy system for chronic skin conditions. The connected system enables a physician to ensure the prescribed dose is delivered while freeing patients from the thrice-weekly office visits often required for treatment of psoriasis, vitiligo and eczema.
DUBLIN – Iomx Therapeutics AG raised €65 million (US$75.4 million) in a series B round, which will enable it to move its lead immuno-oncology program into the clinic. The funding will also allow it to take a second program into IND-enabling studies and to back-fill its pipeline with additional programs.
Exo Therapeutics Inc. has completed an oversubscribed series B financing for $78 million allowing the small-molecule company to continue developing therapies for treating cancer and inflammation.
Exo’s pipeline, created from its Exosight platform, has preclinical candidates that bind exosites, which are distal binding pockets for reprogramming enzyme activity. The exosite drugs include structural and computational biology, protein engineering and DNA-encoded libraries.
Activ Surgical Inc. has closed a $45 million series B financing round to kick off commercialization activities of its augmented reality surgical software suite. Founded in 2017, Boston-based Activ Surgical is preparing to commercialize its first product Activinsights, an FDA-cleared software that provides real-time, intraoperative visual data such as key blood flow identifiers to surgeons.
Expansion Therapeutics Inc., a company developing new drugs for severe RNA-mediated diseases based on the work of its scientific founder, Scripps Research chemistry professor Matthew Disney, has raised $80 million in a series B financing to identify and advance oral small-molecule candidates for the potential treatment of myotonic dystrophy type 1, amyotrophic lateral sclerosis and tauopathies.
DUBLIN – Treefrog Therapeutics SA closed a $75 million series B round this week, which will help to increase its reach and its profile, as it pursues its highly ambitious objective to drive the adoption of a new way of making induced pluripotent stem cells (iPSCs) at scale. The Bordeaux, France-based firm is not a CDMO in any sense, however. It is a fully fledged biotech, with early stage iPSC-based programs in Parkinson’s disease, cardiovascular disease and bone marrow transplant, among others. It’s just that it is also attempting to revolutionize how those cells are cultivated before it administers them as therapies.
RSS
